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Objectives: TOBI® is a nebulized antibiotic for the management of cystic ﬁ-
brosis (CF) patients with Pseudomonas aeruginosa (PA). Each treatment takes
approximately 15 minutes not including time for preparation and cleaning, thus,
potentially burdensome to CF patients who are on multiple therapies. To describe
the treatment pattern of TOBI® use and prescription adherence among CF patients.
Methods: Data were derived from MarketScan Research Databases. CF patients
with an initial claim for a PA infection were identiﬁed during 2005–2008 using
ICD-9-CM codes of 277.0 and 482.1. Patients were included if they initiated TOBI®
and remained on the drug (mono-therapy group), switched to another antibiotic
(switched group), or received other antibiotics in addition (combination group).
Adherence was calculated using medication possession ratio (MPR). All statistical
analyses were conducted using SAS version 9.2.
Conclusion: A total of 134 subjects met the full study criteria and 70% (n = 94)
had a valid pharmacy claim for TOBI®. Of these, 40% were classiﬁed as mono-
therapy, 46% combination and 14% as switchers. Average adjusted number of non-
treatment days in the study sample over 12-months was 224 (SD= 132.0). Subjects
in the combination cohort had the highest treatment days (mean = 164, SD= 135.4)
compared to those that were either switched (mean = 86, SD= 81.2) or on mono-
therapy (mean = 135, SD= 137.7). Overall mean MPR was 0.39 (SD= 0.36). Ad-
herence to TOBI prescriptions among CF patients with PA was low considering the
complex and chronic nature of this disease. Burden associated with novel medication
administration need to be explored to improve adherence.
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Staphylococcus aureus is one of most frequently isolated organism in respira-
tory secretions of cystic ﬁbrosis (CF) patients. Whereas recent data conﬁrms its
pathogenic role in pulmonary pathogenic colonization and inﬂammation, which
ﬁnally result in bronchiectasis, optimal treatment has not been established. The
management of 13 CF-patients with chronic symptomatic methicillin-susceptible
S. aureus (MSSA) lung infection that were daily treated with nebulized ampicillin
(500mg b.i.d in <40 kg and 1 g b.i.d.in >40 kg) for a period between 6 and
45 months (mean: 23 months) were analyzed. A signiﬁcant decrease in the days of
oral antibiotic that patients required (from 28 to of 7 days/year) (P = 0.033) and in
the number of hospital admissions (P = 0.046) was observed. During the treatment,
Haemophilus parainﬂuenzae co-colonization was detected in all patients, whereas
chronic colonization with Pseudomonas aeruginosa was not observed. S. aureus
was not eradicated and bacterial load in the sputum were maintained. High clonal
diversity (8 clones in 10 patients) was observed with potential cross transmission
in two patients. With the exception of two patients, clonal persistence without
new S. aureus clone acquisition was also demonstrated. No severe side effects
were associated with ampicillin inhalation. Our results suggest that chronically
nebulized ampicillin could be effective and safe in CF-patients chronically infected
by MSSA. Its use might be indicated in patients with poor symptom control or
frequent exacerbations.
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Objective: Arikace™ is an aqueous liposomal dispersion of amikacin for inhala-
tion being developed for the treatment of P. aeruginosa (Pa) infection in CF
patients (pts). The primary objective of the study was to evaluate the long-term
effects of multiple cycles (cy) of treatment with Arikace.
Methods: This is a multi-cycle, open-label study conducted in 11 centers in
Europe. Pts 6 years (yr) & above who were previously enrolled in the placebo
controlled study of Arikace were consented to participate in this 6 cy, 18 month (mo)
study. Each cy is comprised of 28 days (d) of treatment with 560mg of Arikace
by inhalation with PARI eFlow® nebulizer followed by 56 d off drug. Safety,
pharmacokinetics, Pa sputum density, Quality of Life (CFQ-R) & exacerbation
rate are evaluated every 2 weeks.
Results: 49 pts were enrolled. 43 pts, 42 pts, & 41 pts have completed 4, 5, &
6 cy respectively. Baseline mean age is 17.3 yr; FEV1(%pred) is 60.1%; male
41.7%; female 58.3%. Overall, Arikace 560mg administered once daily for 6 cy
is well tolerated & demonstrates adverse effects consistent with those expected in
a population of CF pts. Available data from 6 cy show an average increase from
baseline in FEV1(%) of 12.2% at the end of treatment over 6 cy (p = 0.0002) &
sustained increase of 5.6% 56 d off drug at end of 6 cy (p = 0.0019). Up to 1.3 log
reduction in Pa was also seen. Analysis of complete data for all patients will be
available at ECFS.
Conclusion: Arikace 560mg given once daily for 28d for 6 cy is well tolerated in
CF pts. An increase in FEV1(%) signiﬁcantly above baseline is observed during
treatment period of each cy which is sustained during the 56d off study drug
indicating patient beneﬁt.
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Introduction: A lyophilized formulation of aztreonam for nebulisation was avail-
able for use on a compassionate basis from early 2009 in the U.K. This was for
patients with an aztreonam sensitive strain of Pseudomonas aeruginosa that could
not be treated with other available nebulised antibiotics. Seven adult patients in our
unit were eligible for treatment.
Objectives: To assess the impact of treatment on lung function and intravenous
antibiotic use.
Method: Data was retrospectively collected from medical records of all patients
(n = 7) that received a test dose of aztreonam. FVC (L), FEV l/s and FEF25−75 l/s
were measured, at baseline and every two to three months after the initiation of
therapy until the end of 2010. Percent change in lung function from baseline was
calculated and the number of intravenous antibiotic courses pre and post initiation
of therapy was compared.
Results: Therapy was discontinued in 1/7 patients on initiating therapy due to
bronchospasm. The remaining 6 patients continued treatment on a month on and
month off cycle. To date, four subjects have completed 14 months treatment with
a further two patient having completed 12 and nine months respectively. Lung
function improved from baseline in 50% of cases while in three patients values
declined. In 4/5 subjects the number IV antibiotic courses fell signiﬁcantly. In
the remaining two subjects, one needed continuous iv antibiotics and the other
augmentation of treatment.
Conclusion: In this small number of patients, nebulised aztreonam therapy im-
proved lung function in 50% of patients while reducing the requirement for
intravenous antibiotics in 66%.
